Docetaxel: Verso Nuovi Impieghi Nel Trattamento Dei Tumori Solidi

Ravdin P.M. , Burris H.A. , Cook G. , Eisenberg P. , Kane M. , Bierman W.A. , Mortimer J. , Genevois E. , Bellet R.E. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879–2885, 1995.

Valero V. , Holmes F.A. , Walters R.S. , Theriault R.L. , Esparza L. , Fraschini G. , Fonseca G.A. , Bellet R.E. , Buzdar A.U. , Hortobagyi G.N. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886–2894, 1995.

Nabholtz J.M. , Senn H.J. , Bezwoda W.R. , Melnychuk D. , Deschenes L. , Douma J. , Vandenberg T.A. , Rapoport B. , Rosso R. , Trillet-Lenoir V. , Drbal J. , Molino A. , Nortier J.W.R. , Richel D.J. , Nagykalnai T. , Siedlecki P. , Wilking N. , Geot J.Y. , Hupperets P.S.G.J. , Pannuti F. , Skarlos D. , Tomiak E.M. , Murawsky M. , Alakl M. , Riva A. , Aapro M. for the 304 Study Group: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413–1424, 1999.

Sjöström J. , Blomqvist C. , Mouridsen H. , Pluzanska A. , Ottosson-Lönn S. , Bengtsson N.O. , Østenstadd B. , Mjaaland I. , Palm-Syövall M. , Wist E. , Valvere V. , Anderson H. , Bergh J. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194–1201, 1999.

Bonneterre J. , Roche H. , Monnier A. , Serin D. , Fargeot P. , Guastalla J.P. , Rios M. , Namer M. , Culine S. , Tubiana M. , Assadourian S. , Gaudin I. Taxotere, (TXT) versus 5-fluorouracil + Navelbine, (FUN) as second line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) (preliminary results). Proc ASCO 16: 564 (abst), 1997.

Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzáles Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J for the 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341–2354, 1999.

Paridaens R. , Biganzoli L. , Bruning P. , Klijn J.G. , Gamucci T. , Houston S. , Coleman R. , Schachter J. , Van Vreckem A. , Sylvester R. , Awada A. , Wildiers J. , Piccart M. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research Treatment of Cancer randomized study with cross-over. J Clin Oncol 18(4): 724–733, 2000.

Sledge G.W. Jr ., Neuberg D. , Ingle J. , Martino S. , Wood W. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc ASCO 16: 2 (abst), 1997.

Misset J.L. , Dieras V. , Gruia G. , Bourgeois H. , Cvitkovic E. , Kalla S. , Bozec L. , Beuzeboc P. , Jasmin C. , Aussel J.P. , Riva A. , Azli N. , Pouillart P. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 10: 553–560, 1999.

Nabholtz JM, Falkson G, Campos D, Szanto J, Martin M, Chan S, Pienkowsi T, Bezwoda WR, Zaluski J, Pinter T, KrzaKowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P on behalf of the international TAX 306 study group. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. Proc ASCO 18: 485 (abst), 1999.

Nabholtz J.M. , Paterson A. , Dirix L. , Dewar J. , Chap L. , Martin M. , Chan S. , Tang S. , Dugan W. , Gil M. , Zaluski J. , Russel C. , Vogel C. , Borg-Olivier O. , Riva A. , Murawsky M. , Azli N. , Efremidis A. A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc ASCO 20: 83 (abst), 2001.

Bonneterre J. , Dieras V. , Tubiana-Hulin M. , Bougnoux P. , Bonneterre M. , Delozier T. , Culine S. , Dohollou N. , Suissa J. , Samak R. Six cycles of epirubicin/docetaxel (ET) versus six cycles of 5FU/epirubicin/cyclophosphamide (FEC) as first-line metastatic breast cancer (MBC) treatment. Proc ASCO 20: 163 (abst), 2001.

Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C for the Central and Eastern Europe and Israel Paclitaxel Breast Cancer Study Group. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707–1715, 2001.

Biganzoli L. , Cufer T. , Bruning P. , Coleman R. , Calvert H. , Gamucci T. , Twelves C. , Donato di Paola E. , Duchateau L. , Yague C. , Epelbaum R. , Piccart M. Doxorubicin(A)/taxol(P) versus doxorubicin/cyclophosphamide (C) as first-line chemotherapy in metastatic breast cancer (MBC): a phase III study. Proc ASCO 19: 282 (abst), 2000.

Carmichael J. UKCCCCR trial of epirubicin and cyclophosphamide (EC) vs epirubicin and taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc ASCO 20: 84 (abst), 2001.

Luck H.J. , Thomssen C. , Untch M. , Kuhn W. , Eidtmann H. , du Bois A. , Olbricht S. , Moebus V. , Steinfeld D. , Bauknecht T. , Schroeder W. , Jackisch C. Multicentric phase III study in first-line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc ASCO 19: 280 (abst), 2000.

Konecny G. , Thomssen C. , Pegram M. , Luck H. , Untch M. , Pauletti G. , Dandekar U. , Ramos L. , Kuhn W. , Eidtmann H. , DuBois A. , Olbricht S. , Steinfeld D. , Moebus V. , Minckwitz G.V. , Slamon D. HER-2/neu amplification and response to paclitaxel in patients with metastatic breast cancer. Proc ASCO 20: 88 (abst), 2001.